Close Menu

NEW YORK – Meridian Bioscience reported on Friday that its fiscal first quarter revenues decreased 8 percent year over year partially due to lower contract pricing for certain gastrointestinal products.

For the three months ended Dec. 31, 2019 the firm reported revenues of $47.4 million, down from $51.5 million a year ago. Meridian missed the average Wall Street estimate of $48.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.